Alpha nuclides are featured with characteristics of high radiolucent energy, short range, strong radiobiol. effects and cytotoxic effects, and are currently considered to have a good application prospect for internal radiation therapy of a variety types of of cancers. At present, the number of α-nuclides suitable for labeling therapeutic α-nuclide radiopharmaceuticals is limited, and it is very difficult to prepare and purify them. Therefore, most α-nuclide radiopharmaceuticals are still kept in the clin. research stage. The quality control of radiopharmaceuticals is essential for patient medication safety and is also an important promotion for the study of α-nuclide radiopharmaceuticals. In this paper, the international and domestic status of the study of α-nuclide radiopharmaceuticals is reviewed, and the feasibility study strategies of quality control items, such as phys. identification and radionuclide purity of common and most promising α-radionuclides (223Ra, 225Ac, etc.), are proposed according to the properties of nuclides. It is believed in the field that with the continuous deepening of the quality control study of α-nuclide radiopharmaceuticals in research community of China, it will certainly promote the early marketing ofα-nuclide radiopharmaceuticals in China.